News
LGND
286.94
-3.94%
-11.77
Weekly Report: what happened at LGND last week (1109-1113)?
Weekly Report · 3d ago
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Dow Jones · 11/11 15:35
Ligand Pharmaceuticals Price Target Raised to $350.00/Share From $345.00 by Barclays
Dow Jones · 11/11 15:35
Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350
Benzinga · 11/11 15:25
Ligand price target raised to $350 from $345 at Barclays
TipRanks · 11/11 10:20
Barclays Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks · 11/11 09:15
Weekly Report: what happened at LGND last week (1102-1106)?
Weekly Report · 11/09 09:45
Ligand Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 11/05 22:33
Ligand Pharmaceuticals Price Target Raised to $402.00/Share From $397.00 by Citigroup
Dow Jones · 11/05 22:33
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402
Benzinga · 11/05 22:23
Analysts Conflicted on These Healthcare Names: Ligand Pharma (LGND) and Insulet (PODD)
TipRanks · 11/05 12:03
Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy
Seeking Alpha · 11/04 21:21
Leerink Partners Reaffirms Their Buy Rating on Ligand Pharma (LGND)
TipRanks · 11/02 16:43
RBC Capital Sticks to Its Buy Rating for Ligand Pharma (LGND)
TipRanks · 11/02 15:28
Weekly Report: what happened at LGND last week (1026-1030)?
Weekly Report · 11/02 09:45
Royalty Buyout Options Pose Revenue and Cash‑Flow Risks for Ligand Pharmaceuticals
TipRanks · 11/01 05:00
Ligand Pharma (LGND) Gets a Buy from Bank of America Securities
TipRanks · 10/30 16:56
Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 10/30 16:35
Ligand Pharmaceuticals Price Target Raised to $357.00/Share From $345.00 by RBC Capital
Dow Jones · 10/30 16:35
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357
Benzinga · 10/30 16:26
More
Webull provides a variety of real-time LGND stock news. You can receive the latest news about Ligand Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.